NASDAQ:ADMS - Adamas Pharmaceuticals Stock Price, Forecast & News

Adamas Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADMS."

Adamas Pharmaceuticals Inc (NASDAQ:ADMS) issued its quarterly earnings results on Thursday, November, 7th. The specialty pharmaceutical company reported ($0.99) EPS for the quarter, missing the Zacks' consensus estimate of ($0.90) by $0.09. The specialty pharmaceutical company had revenue of $13.93 million for the quarter, compared to analysts' expectations of $14.36 million. Adamas Pharmaceuticals had a negative net margin of 215.09% and a negative return on equity of 205.30%. View Adamas Pharmaceuticals' Earnings History.

Adamas Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 2nd 2020. View Earnings Estimates for Adamas Pharmaceuticals.

Adamas Pharmaceuticals updated its FY 2019 Pre-Market earnings guidance on Wednesday, January, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $54.6-54.6 million, compared to the consensus revenue estimate of $53.65 million.

10 equities research analysts have issued 1-year price targets for Adamas Pharmaceuticals' stock. Their forecasts range from $5.00 to $55.00. On average, they expect Adamas Pharmaceuticals' stock price to reach $15.67 in the next year. This suggests a possible upside of 179.8% from the stock's current price. View Analyst Price Targets for Adamas Pharmaceuticals.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adamas Pharmaceuticals in the last year. There are currently 2 sell ratings, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Adamas Pharmaceuticals.

News stories about ADMS stock have trended somewhat positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Adamas Pharmaceuticals earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news articles about the specialty pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Adamas Pharmaceuticals.

Adamas Pharmaceuticals saw a increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,380,000 shares, an increase of 28.6% from the December 31st total of 1,850,000 shares. Based on an average daily volume of 641,000 shares, the days-to-cover ratio is currently 3.7 days. Approximately 10.7% of the shares of the company are sold short. View Adamas Pharmaceuticals' Current Options Chain.

Some companies that are related to Adamas Pharmaceuticals include Flexion Therapeutics (FLXN), XBiotech (XBIT), Phoenix Tree (IMAB), Urogen Pharma (URGN), Atreca (BCEL), Kadmon (KDMN), ZIOPHARM Oncology (ZIOP), AC Immune (ACIU), Kura Oncology (KURA), Crinetics Pharmaceuticals (CRNX), Neoleukin Therapeutics (NLTX), Assembly Biosciences (ASMB), Molecular Templates (MTEM), Axovant Sciences (AXON) and CytoDyn (CYDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Adamas Pharmaceuticals investors own include Rite Aid (RAD), Agile Therapeutics (AGRX), Amarin (AMRN), Sangamo Therapeutics (SGMO), Inovio Pharmaceuticals (INO), Nabriva Therapeutics (NBRV), TG Therapeutics (TGTX), AcelRx Pharmaceuticals (ACRX), Exelixis (EXEL) and Abeona Therapeutics (ABEO).

Adamas Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Emerald Advisers LLC (2.26%), Emerald Mutual Fund Advisers Trust (2.00%), State Street Corp (1.51%), Deltec Asset Management LLC (1.43%), Panagora Asset Management Inc. (1.08%) and Renaissance Technologies LLC (1.05%). Company insiders that own Adamas Pharmaceuticals stock include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went, Jennifer J Rhodes, Rajiv Patni and Richard King. View Institutional Ownership Trends for Adamas Pharmaceuticals.

ADMS stock was sold by a variety of institutional investors in the last quarter, including Deltec Asset Management LLC, Goldman Sachs Group Inc., Bank of America Corp DE, Emerald Mutual Fund Advisers Trust, Jane Street Group LLC, Emerald Advisers LLC and Bank of New York Mellon Corp. Company insiders that have sold Adamas Pharmaceuticals company stock in the last year include Alfred G Merriweather, Christopher B Prentiss, Gregory T Went and Jennifer J Rhodes. View Insider Buying and Selling for Adamas Pharmaceuticals.

ADMS stock was bought by a variety of institutional investors in the last quarter, including Panagora Asset Management Inc., Renaissance Technologies LLC, DCF Advisers LLC, Virtu Financial LLC, Jacobs Levy Equity Management Inc., AQR Capital Management LLC, Oxford Asset Management LLP and Connor Clark & Lunn Investment Management Ltd.. View Insider Buying and Selling for Adamas Pharmaceuticals.

Shares of ADMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ADMS stock can currently be purchased for approximately $5.60.

Adamas Pharmaceuticals has a market capitalization of $156.00 million and generates $34.05 million in revenue each year. The specialty pharmaceutical company earns $-131,000,000.00 in net income (profit) each year or ($4.87) on an earnings per share basis. Adamas Pharmaceuticals employs 159 workers across the globe.View Additional Information About Adamas Pharmaceuticals.

The official website for Adamas Pharmaceuticals is http://www.adamaspharma.com/.

Adamas Pharmaceuticals' mailing address is 1900 POWELL ST. SUITE 1000, EMERYVILLE CA, 94608. The specialty pharmaceutical company can be reached via phone at 510-450-3500 or via email at [email protected]